Literature DB >> 12031542

Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2.

Eun Joo Kim1, Kyoung Ja Kwon, Jee Young Park, Soo Hwan Lee, Chang Hyun Moon, Eun Joo Baik.   

Abstract

In neurodegenerative disease, the use of non-steroidal anti-inflammatory drugs (NSAIDs) has been regarded as beneficial. The NSAID, an inhibitor of cyclooxygenase (COX), has been also suggested as a ligand of the peroxisome proliferator-activated receptor (PPAR). In cortical neuron-glial co-cultures, we examined the effect of PPAR agonists on lipopolysaccharide(LPS)-induced neuronal death, which has been known to be NO-dependent. LPS induced iNOS expression and the release of nitric oxide in microglia, and COX-2 expression in neurons. PPAR-gamma agonists such as 15d-PGJ(2), ciglitazone and troglitazone prevented LPS-induced neuronal death and abolished LPS-induced NO and PGE(2) release, however PPAR-alpha agonists such as clofibrate and WY14,643 did not produce the same results. PPAR-gamma agonists also reduced LPS-induced iNOS and COX-2 expression, which suggested by interfering with the NF-kappaB signal pathway.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12031542     DOI: 10.1016/s0006-8993(02)02480-0

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  40 in total

1.  Molecular pathology of cerebral TNF-α, IL-1β, iNOS and Nrf2 in forensic autopsy cases with special regard to deaths due to environmental hazards and intoxication.

Authors:  Si-Hao Du; Xiao-Hui Tan; Rui Zhao; Dong Zhao; Ye Xue; Hui-Jun Wang; Xiao-Li Xie; Qi Wang
Journal:  Forensic Sci Med Pathol       Date:  2017-08-03       Impact factor: 2.007

2.  PPARs: a new target for neuroprotection.

Authors:  R Bordet; P Gelé; P Duriez; J-C Fruchart
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-03       Impact factor: 10.154

3.  Protection of neurons and microglia against ethanol in a mouse model of fetal alcohol spectrum disorders by peroxisome proliferator-activated receptor-γ agonists.

Authors:  Cynthia J M Kane; Kevin D Phelan; Lihong Han; Renea R Smith; Jin Xie; James C Douglas; Paul D Drew
Journal:  Brain Behav Immun       Date:  2011-03-03       Impact factor: 7.217

Review 4.  Neuroprotective mechanisms of peroxisome proliferator-activated receptor agonists in Alzheimer's disease.

Authors:  Rupinder K Sodhi; Nirmal Singh; Amteshwar S Jaggi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-05-24       Impact factor: 3.000

5.  Isoorientin attenuates lipopolysaccharide-induced pro-inflammatory responses through down-regulation of ROS-related MAPK/NF-κB signaling pathway in BV-2 microglia.

Authors:  Li Yuan; Yuchen Wu; Xiaomeng Ren; Qian Liu; Jing Wang; Xuebo Liu
Journal:  Mol Cell Biochem       Date:  2013-10-11       Impact factor: 3.396

Review 6.  Thermodynamics in Neurodegenerative Diseases: Interplay Between Canonical WNT/Beta-Catenin Pathway-PPAR Gamma, Energy Metabolism and Circadian Rhythms.

Authors:  Alexandre Vallée; Yves Lecarpentier; Rémy Guillevin; Jean-Noël Vallée
Journal:  Neuromolecular Med       Date:  2018-03-23       Impact factor: 3.843

7.  The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B.

Authors:  L P Quinn; B Crook; M E Hows; M Vidgeon-Hart; H Chapman; N Upton; A D Medhurst; D J Virley
Journal:  Br J Pharmacol       Date:  2008-03-10       Impact factor: 8.739

8.  Agonism of Peroxisome Proliferator Receptor-Gamma may have Therapeutic Potential for Neuroinflammation and Parkinson's Disease.

Authors:  L Hunter Randy; Bing Guoying
Journal:  Curr Neuropharmacol       Date:  2007-03       Impact factor: 7.363

Review 9.  Modulating microglia activity with PPAR-γ agonists: a promising therapy for Parkinson's disease?

Authors:  Anna R Carta; Augusta Pisanu
Journal:  Neurotox Res       Date:  2012-08-07       Impact factor: 3.911

10.  Rosiglitazone inhibits hypercholesterolaemia-induced myeloperoxidase upregulation--a novel mechanism for the cardioprotective effects of PPAR agonists.

Authors:  Hui-Rong Liu; Ling Tao; Erhe Gao; Yan Qu; Wayne Bond Lau; Bernard L Lopez; Theodore A Christopher; Walter Koch; Tian-Li Yue; Xin-Liang Ma
Journal:  Cardiovasc Res       Date:  2008-11-14       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.